This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
BMY Reports Positive Data on Sotyktu From Arthritis Study
by Zacks Equity Research
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
NVSNegative Net Change BMYPositive Net Change BAYRYPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
by Zacks Equity Research
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
SNYNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Insmed Stock Jumps 29% on Encouraging PAH Study Results
by Zacks Equity Research
INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
UTHRPositive Net Change INSMPositive Net Change LQDAPositive Net Change
biotechs medical
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
by Sundeep Ganoria
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
VRTXNegative Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs cancer crispr gene-editing gene-therapy healthcare medical
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
by Zacks Equity Research
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
GSKNegative Net Change NVSNegative Net Change GILDNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
by Zacks Equity Research
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
SNYNegative Net Change AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals vaccines
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
AZNNegative Net Change NVSNegative Net Change BMYPositive Net Change PFEPositive Net Change LLYNegative Net Change ABBVPositive Net Change FATEPositive Net Change
biotechs cancer pharmaceuticals
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
by Zacks Equity Research
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
ALNYNegative Net Change BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
by Sundeep Ganoria
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
JNJNegative Net Change LLYNegative Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
by Ekta Bagri
SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.
REGNNegative Net Change SNYNegative Net Change NVSNegative Net Change BMYPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
by Zacks Equity Research
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
KURA Stock Rises More Than 15% This Past Week: Here's Why
by Zacks Equity Research
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
LXRXNegative Net Change AMRNNegative Net Change KURAPositive Net Change CMMBNegative Net Change
biotechs
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
by Zacks Equity Research
Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data.
RHHBYNegative Net Change LXRXNegative Net Change CMMBNegative Net Change TPSTNegative Net Change
biotechs
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
by Ekta Bagri
ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.
GRFSNegative Net Change ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
by Ekta Bagri
BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
by Sundeep Ganoria
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
REGNNegative Net Change AZNNegative Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change ZTSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
by Zacks Equity Research
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change LYRANegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector
by Zacks Equity Research
With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same gene-delivery method.
RHHBYNegative Net Change SRPTNegative Net Change AGENNegative Net Change IMCRNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
by Zacks Equity Research
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.
REGNNegative Net Change SNYNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
by Zacks Equity Research
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.
JNJNegative Net Change BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
by Zacks Equity Research
MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.
SNYNegative Net Change BMYPositive Net Change MRKPositive Net Change MLTXPositive Net Change
biotechs medical pharmaceuticals
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
by Zacks Equity Research
Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.
VRTXNegative Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
by Zacks Equity Research
Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.
SNYNegative Net Change BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
by Urmimala Biswas
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
BSXNegative Net Change AMGNNegative Net Change DXCMNegative Net Change ABBVPositive Net Change CTRENegative Net Change CHCTPositive Net Change
biotechnology biotechs healthcare medical medical-devices pharmaceuticals